5Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease[J]. Am J Hematol, 2007, 82(10): 916-9.
6Herishanu Y, Polliack A, Leider-Trejo L, et al. Fatal interstitial pneumonitis related to rituximab-containing regimen [J]. Clin Lymphoma Myeloma, 2006, 6(5): 407-9.
7Cha SI, Choi KJ, Shin KM, et al. Risk factors for rituximab-induced interstitial lung diseases in patients with malignant lymphoma [J]. Respiration,2013, 85(2): 175.
8Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma[J]. N Engl J Med, 2008, 359(6): 613-26.
9Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmaeytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) ~J]. Leukemia, 2009, 23(1):153-61.
10Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of dtuximab for adults with idiopathic thrombocytopenic purpura[J]. Ann Intern Med, 2007, 146(1): 25-33.
